These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 23237675)
21. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. Kraus JA; Wenghoefer M; Glesmann N; Mohr S; Beck M; Schmidt MC; Schröder R; Berweiler U; Roggendorf W; Diete S; Dietzmann K; Heuser K; Müller B; Fimmers R; von Deimling A; Schlegel U J Neurooncol; 2001 May; 52(3):263-72. PubMed ID: 11519857 [TBL] [Abstract][Full Text] [Related]
22. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors. Rathore A; Kamarajan P; Mathur M; Sinha S; Sarkar C Pathol Oncol Res; 1999; 5(1):21-7. PubMed ID: 10079373 [TBL] [Abstract][Full Text] [Related]
23. Molecular genetics of radiographically defined de novo glioblastoma multiforme. Tortosa A; Ino Y; Odell N; Swilley S; Sasaki H; Louis DN; Henson JW Neuropathol Appl Neurobiol; 2000 Dec; 26(6):544-52. PubMed ID: 11123721 [TBL] [Abstract][Full Text] [Related]
24. Multi-Omics Data Integration and Mapping of Altered Kinases to Pathways Reveal Gonadotropin Hormone Signaling in Glioblastoma. Jayaram S; Gupta MK; Raju R; Gautam P; Sirdeshmukh R OMICS; 2016 Dec; 20(12):736-746. PubMed ID: 27930095 [TBL] [Abstract][Full Text] [Related]
25. G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues. Cherry AE; Stella N Neuroscience; 2014 Oct; 278():222-36. PubMed ID: 25158675 [TBL] [Abstract][Full Text] [Related]
26. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Tsai NM; Lin SZ; Lee CC; Chen SP; Su HC; Chang WL; Harn HJ Clin Cancer Res; 2005 May; 11(9):3475-84. PubMed ID: 15867250 [TBL] [Abstract][Full Text] [Related]
27. Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? Vasaikar S; Tsipras G; Landázuri N; Costa H; Wilhelmi V; Scicluna P; Cui HL; Mohammad AA; Davoudi B; Shang M; Ananthaseshan S; Strååt K; Stragliotto G; Rahbar A; Wong KT; Tegner J; Yaiw KC; Söderberg-Naucler C BMC Cancer; 2018 Feb; 18(1):154. PubMed ID: 29409474 [TBL] [Abstract][Full Text] [Related]
28. p53 protein overexpression in astrocytic neoplasms. Cho MY; Jung SH; Kim TS Yonsei Med J; 1995 Dec; 36(6):521-6. PubMed ID: 8599254 [TBL] [Abstract][Full Text] [Related]
29. Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines. Cimini A; Mei S; Benedetti E; Laurenti G; Koutris I; Cinque B; Cifone MG; Galzio R; Pitari G; Di Leandro L; Giansanti F; Lombardi A; Fabbrini MS; Ippoliti R J Cell Physiol; 2012 Mar; 227(3):939-51. PubMed ID: 21503892 [TBL] [Abstract][Full Text] [Related]
30. The DNA methylome of glioblastoma multiforme. Martinez R; Esteller M Neurobiol Dis; 2010 Jul; 39(1):40-6. PubMed ID: 20064612 [TBL] [Abstract][Full Text] [Related]
31. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors. Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155 [TBL] [Abstract][Full Text] [Related]
32. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046 [TBL] [Abstract][Full Text] [Related]
33. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development. Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503 [TBL] [Abstract][Full Text] [Related]
34. SnapShot: glioblastoma multiforme. Kotliarova S; Fine HA Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719 [No Abstract] [Full Text] [Related]
35. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. Venkatesan S; Hoogstraat M; Caljouw E; Pierson T; Spoor JK; Zeneyedpour L; Dubbink HJ; Dekker LJ; van der Kaaij M; Kloezeman J; Berghauser Pont LM; Besselink NJ; Luider TM; Joore J; Martens JW; Lamfers ML; Sleijfer S; Leenstra S Oncotarget; 2016 Sep; 7(36):58435-58444. PubMed ID: 27533080 [TBL] [Abstract][Full Text] [Related]
36. The EGFRvIII variant in glioblastoma multiforme. Gan HK; Kaye AH; Luwor RB J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552 [TBL] [Abstract][Full Text] [Related]
37. Molecular targeted therapy of glioblastoma. Le Rhun E; Preusser M; Roth P; Reardon DA; van den Bent M; Wen P; Reifenberger G; Weller M Cancer Treat Rev; 2019 Nov; 80():101896. PubMed ID: 31541850 [TBL] [Abstract][Full Text] [Related]
38. The role of CD44 in glioblastoma multiforme. Mooney KL; Choy W; Sidhu S; Pelargos P; Bui TT; Voth B; Barnette N; Yang I J Clin Neurosci; 2016 Dec; 34():1-5. PubMed ID: 27578526 [TBL] [Abstract][Full Text] [Related]
39. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3. Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931 [TBL] [Abstract][Full Text] [Related]
40. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]